Bausch Health Companies (TSE:BHC) Stock Price Down 1.4% – Should You Sell?

Bausch Health Companies Inc. (TSE:BHC)’s stock price was down 1.4% during trading on Monday . The stock traded as low as C$7.70 and last traded at C$8.01. Approximately 746,307 shares were traded during mid-day trading, an increase of 109% from the average daily volume of 356,868 shares. The stock had previously closed at C$8.12.

Bausch Health Companies Stock Down 1.4%

The business’s 50 day moving average is C$6.74 and its 200 day moving average is C$9.08. The company has a debt-to-equity ratio of -1,831.94, a quick ratio of 0.58 and a current ratio of 1.19. The stock has a market cap of C$2.08 billion, a price-to-earnings ratio of -11.72, a price-to-earnings-growth ratio of 0.21 and a beta of 0.77.

Insider Activity

In related news, Director John Paulson purchased 754,134 shares of Bausch Health Companies stock in a transaction dated Tuesday, June 10th. The stock was acquired at an average cost of C$6.87 per share, with a total value of C$5,179,392.31. Over the last quarter, insiders have acquired 1,771,371 shares of company stock worth $12,585,871. 11.28% of the stock is owned by corporate insiders.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.